{
  "id": "sequoia:bridgebio",
  "sequoia_id": null,
  "name": "BridgeBio",
  "slug": "bridgebio",
  "description": "BridgeBio develops breakthrough medicines for genetic diseases. Its portfolio of more than 15 drugs, all in various stages of development, addresses everything from genetic skin, cancer- and heart-related issues to renal disease.",
  "website": "https://bridgebio.com/",
  "socials": {
    "linkedin": "https://www.linkedin.com/company/bridgebio/about/"
  },
  "categories": [
    "healthcare"
  ],
  "current_stage": "ipo",
  "first_partnered_year": 2018,
  "partners": [
    "roelof-botha"
  ],
  "primary_partner": "roelof-botha",
  "milestones": {
    "founded_year": 2014,
    "partnered_year": 2018,
    "ipo_year": 2019,
    "acquired_year": null
  },
  "team": [
    {
      "name": "Neil Kumar",
      "role": null
    }
  ],
  "why_partnered": null,
  "source_urls": {
    "directory": "https://sequoiacap.com/our-companies/",
    "profile": "https://sequoiacap.com/companies/bridgebio/"
  }
}
